Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Sponsor
The Methodist Hospital Research Institute
Study ID
NCT00837174
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vorinostat in combination with Bortezomib — DRUG
    Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.

Study Details

The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat) non-Hodgkin Lymphoma, and to determine the safety and tolerability of this regimen.

Key Dates

Start date
Jun 30, 2010
Status verified
Sep 2017
Primary completion
May 31, 2012
Completion
May 31, 2012

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination Vorinostat + Bortezomib
    Six cycle combination therapy with vorinostat and bortezomib.

Primary Outcome Measure

Determine the response rate of this regimen in this patient population. [ Time Frame: 6 cycles ]

Related Studies